ST Pharm Banwol Campus Awarded EcoVadis 'Gold' Medal

[Press Release] On September 6, ST Pharm announced that its Banwol Campus has been awarded a 'Gold' medal from EcoVadis. This recognition comes five years after the company first received a 'Bronze' medal in 2019. EcoVadis is a leading global sustainability rating agency, evaluating companies from 180 countries and approximately 130,000 enterprises based on four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The agency awards medals based on performance, with

HK inno.N-IMBiologics-Y-Biologics Transfer Autoimmune Disease Drug Tech to China

$315.5 million worth of a tech transfer agreement signed for Asia including China [Press Release] On August 16, HK inno.N announced that technology of OXTIMA, an autoimmune disease antibody drug candidate jointly developed by IMBiologics and Y-Biologics, has been transferred to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. This is the second milestone for the company, following a deal with Navigator Medicines in the U.S. in June. The technology transfer agreement, led by IMBiologics, is valued at USD 315.5 million (approximately KRW 430 billion), including an upfront pay

SK bioscience and CEPI Deepen Partnership for Pandemic Prevention, Preparedness and Response

"We must work together as ONE TEAM toward a common goal, the 100 Days Mission to prepare for the next pandemic" [Press Release] SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company and the Coalition for Epidemic Preparedness Innovations (CEPI) a hosted the ´Celebrating Partnership for Pandemic Preparedness: CEPI-SK bioscience Reception’ in Yeoui-do, Seoul on August 29th. The CEPI Board and senior officials visited Korea this week to discuss global collaboration to prevent the spread of infectious diseas

ST Pharm, honored with two awards at the 'Korea Biopharma Excellence Awards 2024'

[Press Release] Experts recognize excellence in mRNA manufacturing capabilities and preventive/therapeutic vaccine development capabilities. ST Pharm announced that the company won two awards at the Korea Biopharma Excellence Awards 2024 held at Convensia in Songdo, Incheon on August 13. First, it won the ‘Bioprocessing Excellence Award in mRNA Manufacturing’ in the Bioprocessing Supplier Excellence Awards category and the 'Most Promising Therapeutic Vaccine' award in the Innovation Excellence A

'LECLAZA' in combination with RYBREVANT Receives First U.S. FDA Approval for a Korea-Born Anticancer Drug

Photo by Yuhan Corporation [Yuhan Corp. Press Release] The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s LECLAZA (approved by FDA as LAZCLUZE)plus Johnson & Johnson’s RYBREVANT(amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Designated as a priority review by the FDA in Fe

Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study

Photo by Lunit [Lunit Press Release] On August 6, Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced that its AI-powered chest X-ray analysis software, Lunit INSIGHT CXR, has demonstrated superior performance in tuberculosis (TB) detection in a large-scale, independent study published in The Lancet Digital Health. Despite being a curable disease, TB remains the world's second leading cause of death from a single infectious agent, with an estimate

Daewoong Pharmaceutical's 'Fexuprazan' Expands into Latin America: Enters $300 Million Market in Mexico, Chile, and Ecuador

Photo by Daewoong [Daewoong Press Release] Daewoong Pharmaceutical’s novel treatment for gastroesophageal reflux disease(GERD), 'Fexuprazan,' is making significant inroads into the Latin American market. On August 8, Daewoong Pharmaceutical announced the official launch of Fexuprazan in Mexico, Chile, and Ecuador. According to IQVIA, a leading pharmaceutical market research firm, the anti-ulcer drug market in these three countries was valued at $300 million (approximately KRW 415.5 billion) last

Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner

Samsung Biologics to embed PSCI principles into business practices for responsible value chain management photo by Samsung Biologics [Samsung Biologics Press Release] Incheon, S. Korea, August 6, 2024 – Samsung Biologics, a global contract development and manufacturing organization(CDMO), announced today that the company has joined the Pharmaceutical Supply Chain Initiative(PSCI) as a Supplier Partner. Samsung Biologics is the first Korean CDMO to participate in the PSCI, a group of pharmaceutical and healthcare companies that share a common vision of excellence in safety, environmental, and social

Boryung Hosts 2024 Humans In Space Roadshow in Las Vegas

Boryung promoted Humans In Space by hosting a roadshow at ASCEND, the world's premier space conference. Boryung's CEO and Chairman, Jay Kim, presented at the panel discussion of the 2024 ASCEND(Photo by Boryung) [Boryung Press Release] On August 12, Boryung announced that it hosted the 2024 Humans In Space(HIS) roadshow at the Accelerating Space Commerce, Exploration, and New Discovery(ASCEND), the premier space industry event, held in Las Vegas from July 30 to August 1. ASCEND is an annual space industry conference organized by the American Institute of Aeronautics and Astronautics(AIAA), the wor

Celltrion USA announces incorporation of adalimumab-aaty, a Humira biosimilar, to the Costco Member Prescription Program

Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions Photo by Celltrion [Celltrion Press Release] On August 13, Celltrion USA announced its FDA-approved biosimilar adalimumab-aaty, has been added to the Costco member prescription program. Adalimumab-aaty is a high-concentration(100mg/mL) and citrate-free biosimilar to Humira(adalimumab). Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasi